Quality of life considerations and management in patients with myelodysplastic syndrome

References

• Watson NF, Badr MS, Belenky G, et al. Joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society on the recommended amount of sleep for a healthy adult: methodology and discussion. Sleep. 2015 Aug 1;38(8):1161–1183. doi: 10.5665/sleep.4886
   PubMed Web of Science ®Google Scholar
• Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015 Jun 1;38(6):843–844. doi: 10.5665/sleep.4716
   PubMed Web of Science ®Google Scholar
• Spiegel K, Leproult R, L’Hermite-Balériaux M, et al. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab. 2004 Nov;89(11):5762–5771. doi: 10.1210/jc.2004-1003
   PubMed Web of Science ®Google Scholar
• Sharma N, Hansen CH, O’Connor M, et al. Sleep problems in cancer patients: prevalence and association with distress and pain. Psychooncology. 2012 Sep;21(9):1003–1009. doi: 10.1002/pon.2004
   PubMed Web of Science ®Google Scholar
• Chen D, Yin Z, Fang B. Measurements and status of sleep quality in patients with cancers. Support Care Cancer. 2018 Feb;26(2):405–414. doi: 10.1007/s00520-017-3927-x
   PubMed Web of Science ®Google Scholar
• Lee M, Choh AC, Demerath EW, et al. Sleep disturbance in relation to health-related quality of life in adults: the fels longitudinal study. J Nutr Health Aging. 2009 Jun;13(6):576–583. doi: 10.1007/s12603-009-0110-1
   PubMed Web of Science ®Google Scholar
• Miaskowski C, Lee K, Dunn L, et al. Sleep-wake circadian activity rhythm parameters and fatigue in oncology patients before the initiation of radiation therapy. Cancer Nurs. 2011 Jul;34(4):255–268. doi: 10.1097/NCC.0b013e3181f65d9b
   PubMed Web of Science ®Google Scholar
• Lin S, Chen Y, Yang L, et al. Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients. J Clin Nurs. 2013 May;22(9–10):1281–1290. doi: 10.1111/jocn.12228
   PubMed Web of Science ®Google Scholar
• Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004 Dec;1(3):e62. doi: 10.1371/journal.pmed.0010062
   PubMed Web of Science ®Google Scholar
• Knutson KL, Spiegel K, Penev P, et al. The metabolic consequences of sleep deprivation. Sleep Med Rev. 2007 Jun;11(3):163–178. doi: 10.1016/j.smrv.2007.01.002
   PubMed Web of Science ®Google Scholar
• Spiegel K, Tasali E, Penev P, et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004 Dec 7;141(11):846–850. doi: 10.7326/0003-4819-141-11-200412070-00008
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care. 2001 Dec;10(4):245–255. doi: 10.1046/j.1365-2354.2001.00263.x
   PubMed Web of Science ®Google Scholar
• Steensma DP, Heptinstall KV, Johnson VM, et al. Common troublesome symptoms and their impact on quality of life in patients with Myelodysplastic Syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008 May;32(5):691–698. doi: 10.1016/j.leukres.2007.10.015
   PubMed Web of Science ®Google Scholar
• Luskin MR, Cronin AM, Owens RL, et al. Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 May;177(4):562–566. doi: 10.1111/bjh.14573
   PubMed Web of Science ®Google Scholar
• Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from International multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375–2390. doi: 10.1249/MSS.0000000000002116
   PubMed Web of Science ®Google Scholar
• Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010 Jul;42(7):1409–1426. doi: 10.1249/MSS.0b013e3181e0c112
   PubMed Web of Science ®Google Scholar
• Speck RM, Courneya KS, Mâsse LC, et al. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010 Jun;4(2):87–100. doi: 10.1007/s11764-009-0110-5
   PubMed Web of Science ®Google Scholar
• Efficace F, Cannella L, Cottone F. Pushing the boundaries of care in myelodysplastic syndromes: physical exercise to improve fatigue and health-related quality of life outcomes. Leuk Res. 2016 Oct;49:36–37. doi: 10.1016/j.leukres.2016.08.003
   PubMed Web of Science ®Google Scholar
• Tonosaki A. Impact of walking ability and physical condition on fatigue and anxiety in hematopoietic stem cell transplantation recipients immediately before hospital discharge. Eur J Oncol Nurs. 2012 Feb;16(1):26–33. doi: 10.1016/j.ejon.2011.01.012
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–376. doi: 10.1093/jnci/85.5.365
   PubMedGoogle Scholar
• Smets EM, Garssen B, Bonke B, et al. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995 Apr;39(3):315–325. doi: 10.1016/0022-3999(94)00125-O
   PubMed Web of Science ®Google Scholar
• Schuler MK, Hentschel L, Göbel J, et al. Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome-a pilot study. Leuk Res. 2016 Aug;47:128–135.
   PubMed Web of Science ®Google Scholar
• Rees-Punia E, Patel AV, Fallon EA, et al. Physical activity, sitting time, and risk of myelodysplastic syndromes, acute myeloid leukemia, and other myeloid malignancies. Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1489–1494. doi: 10.1158/1055-9965.EPI-19-0232
   PubMed Web of Science ®Google Scholar
• Courneya KS, Keats MR, Turner AR. Physical exercise and quality of life in cancer patients following high dose chemotherapy and autologous bone marrow transplantation. Psychooncology. 2000 Mar;9(2):127–136. doi: 10.1002/(SICI)1099-1611(200003/04)9:2<127:AID-PON438>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Zimmer P, Oberste M, Bloch W, et al. Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - study protocol of a randomized placebo-controlled trial. Contemp Clin Trials. 2016 Jul;49:1–5.
   PubMed Web of Science ®Google Scholar
• Kroll ME, Murphy F, Pirie K, et al. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK million women study. Br J Cancer. 2012 Aug 21;107(5):879–887. doi: 10.1038/bjc.2012.333
   PubMed Web of Science ®Google Scholar
• Ugai T, Matsuo K, Sawada N, et al. Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan Public health centre-based prospective study. Br J Haematol. 2017 Sep;178(5):747–755. doi: 10.1111/bjh.14749
   PubMed Web of Science ®Google Scholar
• Du Y, Fryzek J, Sekeres MA, et al. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res. 2010 Jan;34(1):1–5. doi: 10.1016/j.leukres.2009.08.006
   PubMed Web of Science ®Google Scholar
• Björk J, Albin M, Mauritzson N, et al. Smoking and myelodysplastic syndromes. Epidemiology. 2000 May;11(3):285–291. doi: 10.1097/00001648-200005000-00010
   PubMed Web of Science ®Google Scholar
• Strom SS, Gu Y, Gruschkus SK, et al. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia. 2005 Nov;19(11):1912–1918. doi: 10.1038/sj.leu.2403945
   PubMed Web of Science ®Google Scholar
• Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012 Jul;125(7 Suppl):S2–5. doi: 10.1016/j.amjmed.2012.04.014
   PubMed Web of Science ®Google Scholar
• Teras LR, Patel AV, Carter BD, et al. Anthropometric factors and risk of myeloid leukaemias and myelodysplastic syndromes: a prospective study and meta-analysis. Br J Haematol. 2019 Jul;186(2):243–254. doi: 10.1111/bjh.15904
   PubMed Web of Science ®Google Scholar
• LoConte NK, Brewster AM, Kaur JS, et al. Alcohol and cancer: a statement of the American Society of Clinical Oncology. J Clin Oncol. 2018 Jan 1;36(1):83–93. doi: 10.1200/JCO.2017.76.1155
   PubMed Web of Science ®Google Scholar
• de Menezes RF, Bergmann A, Thuler LC. Alcohol consumption and risk of cancer: a systematic literature review. Asian Pac J Cancer Prev. 2013;14(9):4965–4972. doi: 10.7314/APJCP.2013.14.9.4965
   PubMedGoogle Scholar
• Liu P, Holman CD, Jin J, et al. Alcohol consumption and risk of myelodysplastic syndromes: a case-control study. Cancer Causes Control. 2016 Feb;27(2):209–216. doi: 10.1007/s10552-015-0698-x
   PubMed Web of Science ®Google Scholar
• Lust S, Vanhoecke B, Janssens A, et al. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res. 2005 Sep;49(9):844–850. doi: 10.1002/mnfr.200500045
   PubMed Web of Science ®Google Scholar
• Gerhäuser C. Beer constituents as potential cancer chemopreventive agents. Eur J Cancer. 2005 Sep;41(13):1941–1954. doi: 10.1016/j.ejca.2005.04.012
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997 Jan 10;275(5297):218–220. doi: 10.1126/science.275.5297.218
   PubMed Web of Science ®Google Scholar
• Clément MV, Hirpara JL, Chawdhury SH, et al. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood. 1998 Aug 1;92(3):996–1002. doi: 10.1182/blood.V92.3.996
   PubMed Web of Science ®Google Scholar
• Jin J, Yu M, Hu C, et al. Alcohol consumption and risk of myelodysplastic syndromes: a meta-analysis of epidemiological studies. Mol Clin Oncol. 2014 Nov;2(6):1115–1120. doi: 10.3892/mco.2014.376
   PubMedGoogle Scholar
• Pekmezovic T, Suvajdzic Vukovic N, Kisic D, et al. A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro). Ann Hematol. 2006 Aug;85(8):514–519. doi: 10.1007/s00277-006-0128-y
   PubMed Web of Science ®Google Scholar
• Avgerinou C, Giannezi I, Theodoropoulou S, et al. Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece. Hematology. 2017 Aug;22(7):419–429. doi: 10.1080/10245332.2016.1277006
   PubMed Web of Science ®Google Scholar
• Sakurai A, Nakazato T. The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine. Leuk Lymphoma. 2020 Dec;61(12):2995–2997. doi: 10.1080/10428194.2020.1791847
   PubMed Web of Science ®Google Scholar
• Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutrición Hospitalaria. 2005 Jan;20(1):38–45.
   PubMedGoogle Scholar
• Xu X, Zhang Q, Hu G, et al. Effect of initial body mass index on survival outcome of patients with myelodysplastic syndrome: a single-center retrospective study. Leuk Lymphoma. 2018 Jan;59(1):129–137. doi: 10.1080/10428194.2017.1330477
   PubMed Web of Science ®Google Scholar
• Kishtagari A, Sekeres MA. Eat and be healthy: nutritional status in myelodysplastic syndromes. Leuk Lymphoma. 2020 Dec;61(12):2788–2789. doi: 10.1080/10428194.2020.1797015
   PubMed Web of Science ®Google Scholar
• Nishiyama-Fujita Y, Nakazato T, Kamiya T, et al. The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine. Hematol Oncol. 2020 Oct;38(4):611–613. doi: 10.1002/hon.2760
   PubMed Web of Science ®Google Scholar
• Bouillanne O, Morineau G, Dupont C, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005 Oct;82(4):777–783. doi: 10.1093/ajcn/82.4.777
   PubMed Web of Science ®Google Scholar
• Poynter JN, Richardson M, Blair CK, et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol. 2016 Feb;40:134–140.
   PubMed Web of Science ®Google Scholar
• Jabbar KJ, Yin CC, Bueso-Ramos CE, et al. Higher body mass index is associated with better survival in patients with myelodysplastic syndromes. Leuk Res. 2018 Aug;71:63–66.
   PubMed Web of Science ®Google Scholar
• Ma X, Lim U, Park Y, et al. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol. 2009 Jun 15;169(12):1492–1499. doi: 10.1093/aje/kwp074
   PubMed Web of Science ®Google Scholar
• Schwabkey Z, Al Ali N, Sallman D, et al. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021 Dec;26(1):393–397. doi: 10.1080/16078454.2021.1929692
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Fracchiolla NS, Bamonti-Catena F, et al. Hyperhomocysteinemia in myelodysplastic syndromes: specific association with autoimmunity and cardiovascular disease. Leuk Lymphoma. 2001 Mar;41(1–2):147–150. doi: 10.3109/10428190109057963
   PubMed Web of Science ®Google Scholar
• Gil Á, Martinez de Victoria E, Olza J. Indicators for the evaluation of diet quality. Nutrición Hospitalaria. 2015 Feb 26;31(Suppl 3):128–144. doi: 10.3305/nh.2015.31.sup3.8761
   PubMedGoogle Scholar
• Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012 Jul;62(4):243–274. doi: 10.3322/caac.21142
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x
   PubMed Web of Science ®Google Scholar
• Ginieri-Coccossis M, Theofilou P, Synodinou C, et al. Quality of life, mental health and health beliefs in haemodialysis and peritoneal dialysis patients: investigating differences in early and later years of current treatment. BMC Nephrol. 2008 Nov 14;9(1):14. doi: 10.1186/1471-2369-9-14
   PubMedGoogle Scholar
• Dimova R, Keskinova D, Tzekov V, et al. Health-related quality of life in end-stage renal disease patients, using the Missoula-Vitas quality of life index: a multicenter study. Med Pharm Rep. 2019 Oct;92(4):374–381. doi: 10.15386/mpr-1320
   PubMedGoogle Scholar
• Thomas ML. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res. 1998 May;22(Suppl 1):S41–7. doi: 10.1016/S0145-2126(98)00055-1
   PubMedGoogle Scholar
• Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol. 1997 Jul;34(3 Suppl 2):4–12.
   PubMed Web of Science ®Google Scholar
• Nail LM, Winningham ML. Fatigue and weakness in cancer patients: the symptoms experience. Semin Oncol Nurs. 1995 Nov;11(4):272–278. doi: 10.1016/S0749-2081(05)80008-7
   PubMedGoogle Scholar
• Nickolich M, El-Jawahri A, LeBlanc TW. Palliative and end-of-life care in myelodysplastic syndromes. Curr Hematol Malig Rep. 2016 Dec;11(6):434–440. doi: 10.1007/s11899-016-0352-z
   PubMed Web of Science ®Google Scholar
• Allart-Vorelli P, Porro B, Baguet F, et al. Haematological cancer and quality of life: a systematic literature review. Blood Cancer J. 2015 Apr 24;5(4):e305. doi: 10.1038/bcj.2015.29
   PubMedGoogle Scholar
• Troy JD, de Castro CM, Pupa MR, et al. Patient-reported distress in myelodysplastic syndromes and its association with clinical outcomes: a retrospective cohort study. J Natl Compr Canc Netw. 2018 Mar;16(3):267–273. doi: 10.6004/jnccn.2017.7048
   PubMed Web of Science ®Google Scholar
• Abel GA, Klaassen R, Lee SJ, et al. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014 Jan 16;123(3):451–452. doi: 10.1182/blood-2013-11-540021
   PubMed Web of Science ®Google Scholar
• McGrath P. Findings on family issues during relocation for Hematology care. Oncol Nurs Forum. 2015 May;42(3):E250–6. doi: 10.1188/15.ONF.E250-E256
   PubMed Web of Science ®Google Scholar
• Bellizzi KM, Miller MF, Arora NK, et al. Positive and negative life changes experienced by survivors of non-Hodgkin’s lymphoma. Ann Behav Med. 2007 Oct;34(2):188–199. doi: 10.1007/BF02872673
   PubMed Web of Science ®Google Scholar
• Papathanasiou IV, Kelepouris K, Valari C, et al. Depression, anxiety and stress among patients with hematological malignancies and the association with quality of life: a cross-sectional study. Med Pharm Rep. 2020 Jan;93(1):62–68. doi: 10.15386/mpr-1502
   PubMedGoogle Scholar
• Davies NJ, Kinman G, Thomas RJ, et al. Information satisfaction in breast and prostate cancer patients: implications for quality of life. Psychooncology. 2008 Oct;17(10):1048–1052. doi: 10.1002/pon.1305
   PubMed Web of Science ®Google Scholar
• Faller H, Koch U, Brähler E, et al. Satisfaction with information and unmet information needs in men and women with cancer. J Cancer Surviv. 2016 Feb;10(1):62–70. doi: 10.1007/s11764-015-0451-1
   PubMed Web of Science ®Google Scholar
• Faller H, Strahl A, Richard M, et al. The prospective relationship between satisfaction with information and symptoms of depression and anxiety in breast cancer: a structural equation modeling analysis. Psychooncology. 2017 Nov;26(11):1741–1748. doi: 10.1002/pon.4358
   PubMed Web of Science ®Google Scholar
• Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014 Aug 7;124(6):873–881. doi: 10.1182/blood-2014-03-563221
   PubMed Web of Science ®Google Scholar
• Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006 May 15;106(10):2087–2094. doi: 10.1002/cncr.21860
   PubMed Web of Science ®Google Scholar
• Pinchon DJ, Stanworth SJ, Dorée C, et al. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol. 2009 Oct;84(10):671–677. doi: 10.1002/ajh.21503
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep. 2003 Mar;2(2):122–129.
   PubMedGoogle Scholar
• Ryblom H, Hast R, Hellström-Lindberg E, et al. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes. Eur J Oncol Nurs. 2015 Apr;19(2):99–106. doi: 10.1016/j.ejon.2014.10.011
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Hofbauer LC, Ehninger G, et al. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012 May;36(5):525–536. doi: 10.1016/j.leukres.2012.01.006
   PubMed Web of Science ®Google Scholar
• Koutsavlis I. Transfusion thresholds, quality of life, and Current approaches in myelodysplastic syndromes. Anemia. 2016;2016:8494738. doi: 10.1155/2016/8494738
   PubMed Web of Science ®Google Scholar
• Nilsson-Ehle H, Birgegård G, Samuelsson J, et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. Eur J Haematol. 2011 Sep;87(3):244–252. doi: 10.1111/j.1600-0609.2011.01654.x
   PubMed Web of Science ®Google Scholar
• Moukalled NM, El Rassi FA, Temraz SN, et al. Iron overload in patients with myelodysplastic syndromes: an updated overview. Cancer. 2018 Oct 15;124(20):3979–3989. doi: 10.1002/cncr.31550
   PubMed Web of Science ®Google Scholar
• Killick SB. Iron chelation therapy in low risk myelodysplastic syndrome. Br J Haematol. 2017 May;177(3):375–387. doi: 10.1111/bjh.14602
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Crit Rev Oncol Hematol. 2017 Sep;117:57–66. doi: 10.1016/j.critrevonc.2017.07.002
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Lovrinov M, Skelin M. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes. Ann Intern Med. 2020 Oct 6;173(7):595. doi: 10.7326/L20-1055
   PubMed Web of Science ®Google Scholar
• Odejide OO, Cronin AM, Condron NB, et al. Barriers to quality end-of-life care for patients with blood cancers. J Clin Oncol. 2016 Sep 10;34(26):3126–3132. doi: 10.1200/JCO.2016.67.8177
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011 Feb 10;29(5):516–523. doi: 10.1200/JCO.2010.31.0854
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223–232. doi: 10.1016/S1470-2045(09)70003-8
   PubMed Web of Science ®Google Scholar
• El-Jawahri A, Kim HT, Steensma DP, et al. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016 Aug;51(8):1121–1126. doi: 10.1038/bmt.2016.40
   PubMed Web of Science ®Google Scholar
• Tinsley SM, Sutton SK, Thapa R, et al. Treatment choices: a quality of life comparison in acute myeloid leukemia and high-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2017 Jul;17:S75–s79.
   Web of Science ®Google Scholar
• LeBlanc TW. Palliative care and hematologic malignancies: old dog, new tricks? J Oncol Pract. 2014 Nov;10(6):e404–7. doi: 10.1200/JOP.2014.000968
   PubMedGoogle Scholar
• LeBlanc TW, El-Jawahri A. When and why should patients with hematologic malignancies see a palliative care specialist? Hematology Am Soc Hematol Educ Program. 2015;2015(1):471–478. doi: 10.1182/asheducation-2015.1.471
   PubMedGoogle Scholar
• LeBlanc TW. Addressing end-of-life quality gaps in hematologic cancers: the importance of early concurrent palliative care. JAMA Intern Med. 2016 Feb;176(2):265–266. doi: 10.1001/jamainternmed.2015.6994
   PubMed Web of Science ®Google Scholar
• Hui D, Didwaniya N, Vidal M, et al. Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer. 2014 May 15;120(10):1572–1578. doi: 10.1002/cncr.28614
   PubMed Web of Science ®Google Scholar
• Odejide OO, Salas Coronado DY, Watts CD, et al. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014 Nov;10(6):e396–403. doi: 10.1200/JOP.2014.001537
   PubMedGoogle Scholar
• LeBlanc TW, O’Donnell JD, Crowley-Matoka M, et al. Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. J Oncol Pract. 2015 Mar;11(2):e230–8. doi: 10.1200/JOP.2014.001859
   PubMed Web of Science ®Google Scholar